Genus (GNS.L) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

GNS.L · Stock Price

GBP 23.56+2.46 (+11.66%)

Market Cap: $2.1B

Historical price data

Market Cap: $2.1BPipeline: 2 drugsPatents: 20Founded: 1994Employees: ~3,500HQ: Basingstoke, United Kingdom

Overview

Genus plc is a FTSE 250-listed biotechnology company with a unique mission: to pioneer animal genetic improvement to sustainably nourish the world. The company has established a dominant global position in porcine and bovine genetics through its proprietary technology platform, which integrates genomic selection, reproductive biology, and data science. Its strategy centers on continuous genetic gain, a resilient global supply chain, and value-based pricing, serving over 50,000 customers in more than 85 countries to enhance protein production efficiency and reduce environmental impact.

Biotech

Technology Platform

An integrated platform combining genomic selection, advanced reproductive technologies (sexing, IVF), gene editing R&D, and bioinformatics to drive continuous genetic improvement in livestock.

Pipeline

2

2 drugs in pipeline

Drug	Indication	Stage	Watch
GO-203-2C + Bortezomib	Multiple Myeloma	Phase 1
GO-203-2c	Solid Tumors	Phase 1

Funding History

1

IPOUndisclosedUndisclosedJun 15, 2000

FDA Approved Drugs

20

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATEANDAFeb 18, 2025

CIPROFLOXACIN HYDROCHLORIDEANDANov 5, 2024

CHLORPROMAZINE HYDROCHLORIDEANDAJun 2, 2021

Opportunities

Genus is leveraged to powerful secular trends: rising global protein demand and the urgent need for sustainable agriculture.

Its genetics offer a cost-effective way to reduce the environmental footprint of livestock.

Expansion in key strategic markets like China (swine) and Latin America (cattle) provides a clear growth runway.

Risk Factors

Key risks include geopolitical and trade tensions impacting key markets like China, regulatory uncertainty surrounding the approval of gene-edited animals, and the cyclical nature of agricultural economies which can affect farmer investment in genetics.

Competitive Landscape

Genus competes in a consolidated global market against players like Topigs Norsvin (swine) and CRV/Semex (cattle). Its competitive moat is built on a proprietary technology platform, dual-species leadership, a global high-health supply chain, and the scale of its performance data, which fuels superior genetic gain.